Featured Research

from universities, journals, and other organizations

New Protein Partnership That Leads To Pediatric Tumor Regression

Date:
September 11, 2009
Source:
Weizmann Institute of Science
Summary:
Scientists have discovered that the cell receptor TrkA may be involved in the spontaneous regression of some pediatric cancers. Further research towards a better understanding of the mechanism of action might hopefully lead, in the future, to the development of drugs that will be able to induce regression of certain tumors.

Why are some pediatric cancers able to spontaneously regress? Prof. Michael Fainzilber and his team of the Weizmann Institute’s Biological Chemistry Department seem to have unexpectedly found part of the answer. Further research towards a better understanding of the mechanism of action might hopefully lead, in the future, to the development of drugs that will be able to induce regression of certain tumors.

TrkA is a particular cell receptor well known for its “pro-life advocacies”: When nerve growth factor proteins bind to TrkA receptors, it activates the receptors into promoting the growth and survival of neurons.

So when Fainzilber, together with Ph.D. student Liraz Harel, postdoctoral student Dr. Barbara Costa, technician Zehava Levy, and former Ph.D. student Dr. Marianna Tcherpakov, carried out screening tests to identify other molecules involved in this signaling cascade, it took them by surprise to learn that TrkA may not be who it seems. They found that if TrkA teams up with another molecule called CCM2 – the newly-identified player in this signaling cascade – they become “partners in crime,” with TrkA turning into a cell killer!

However, though paradoxical, this atypical behavior may actually be rooting for life after all. This idea comes from findings concerning pediatric tumors of neural origin, specifically, medulloblastoma – the most common malignant brain tumor and the second most common malignancy among children less than 20 years of age; and neuroblastoma – the most common extracranial solid cancer in childhood. Neuroblastoma displays unusual behavior, being one of the few human malignancies known to demonstrate spontaneous regression in some cases, but nobody knows how or why. Studies have shown that the tumors with positive prognosis usually express TrkA, while aggressive forms of the tumor do not. However, how TrkA induces tumor regression is yet unknown, and the mechanism was an enigma.

What if CCM2 was the missing piece to the tumor regression puzzle? Together with a group of scientists in Germany who were conducting a large scale gene expression study in tumors from neuroblastoma patients, they checked the expression levels of CCM2 and TrkA from the patient samples collected. The results were clear-cut: TrkA and CCM2 were always expressed together in certain tumors – those that showed the highest incidences of regression and patient survival.

They confirmed their results by blocking the expression of either TrkA or CCM2 in some cells, which resulted in cell survival. On the other hand, by introducing CCM2 to cells lacking it, cell death was induced if TrkA was also present, suggesting that this mechanism could lead to tumor regression.

This research, recently published in Neuron, is one of the first to elucidate this paradoxical “pro-cell death” behavior of TrkA, and the first to identify CCM2 as a crucial accessory in this particular pathway. They have even described in detail just how these two molecules interact.

Prof. Michael Fainzilber’s research is supported by the M.D. Moross Institute for Cancer Research; the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; the Helen and Martin Kimmel Institute for Stem Cell Research; the Irving B. Harris Foundation; and Mr. and Mrs. Michael Salzberg, Bethesda, MD. Prof. Fainzilber is the incumbent of the Chaya Professorial Chair for Molecular Neuroscience.


Story Source:

The above story is based on materials provided by Weizmann Institute of Science. Note: Materials may be edited for content and length.


Cite This Page:

Weizmann Institute of Science. "New Protein Partnership That Leads To Pediatric Tumor Regression." ScienceDaily. ScienceDaily, 11 September 2009. <www.sciencedaily.com/releases/2009/09/090910103327.htm>.
Weizmann Institute of Science. (2009, September 11). New Protein Partnership That Leads To Pediatric Tumor Regression. ScienceDaily. Retrieved September 3, 2014 from www.sciencedaily.com/releases/2009/09/090910103327.htm
Weizmann Institute of Science. "New Protein Partnership That Leads To Pediatric Tumor Regression." ScienceDaily. www.sciencedaily.com/releases/2009/09/090910103327.htm (accessed September 3, 2014).

Share This



More Health & Medicine News

Wednesday, September 3, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Doctors Fear They're Losing Battle Against Ebola

Doctors Fear They're Losing Battle Against Ebola

AP (Sep. 2, 2014) As a third American missionary is confirmed to have contracted Ebola in Liberia, doctors on the ground in West Africa fear they're losing the battle against the outbreak. (Sept. 2) Video provided by AP
Powered by NewsLook.com
Tech Giants Bet on 3D Headsets for Gaming, Healthcare

Tech Giants Bet on 3D Headsets for Gaming, Healthcare

AFP (Sep. 2, 2014) When Facebook acquired the virtual reality hardware developer Oculus VR in March for $2 billion, CEO Mark Zuckerberg hailed the firm's technology as "a new communication platform." Duration: 02:24 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins